ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1219

Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population

‪Gabriel Breuer‬‏1, Marwan Abu Sneineh‬‏ 1 and Gideon Nesher 1, 1Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: administrative databases and prognostic factors, Comorbidity, hyperuricemia, morbidity and mortality

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Hyperuricemia is associated with the development, progression and outcome of several diseases. The purpose of this study is to evaluate the serum uric acid (UA) levels as predictor of long-term mortality in elderly population aged 60 years and above. In a previous study we showed that short term mortality is inversely related to uric acid levels (Table 1).

Methods: Patients older than 60 years who were hospitalized in the departments of geriatrics and internal medicine in one medical center during a period of 4 months (March-June 2014) were included in this observational study. Data on clinical parameters and UA levels were collected during the first 48 hours of their hospitalization. The short-term mortality of this cohort was reported in a previous study, and we have continued to follow this cohort for 3.5 more years. Mortality data had been collected from databases of the Ministry of Internal Affairs, and the major medical centers in Jerusalem. Excluded were patients for whom mortality data were missing (unknown status or date of mortality). Demographic and clinical data were collected on admission including UA serum levels within 48 hours from admission Effect of UA serum levels and all relevant confounding parameters on all-cause mortality was assessed using regression analyses.

Results: 624 patients were included in our study. Mean age was 77.2 ± 14.6 years. Overall, 381 patients died during the follow up period (61.1%). Mortality rate in the hyperuricemic group (UA > 7 mg/dl) was higher (69.1%) than in normo-uricemic patients (58.4%, p= 0.004). The median survival for hyperuricemic patients was significantly shorter compared to normo-uricemic patients (606 and 1018 days, respectively, (p< .0001). (Figure 1)

Conclusion: Elevated levels of UA in an acute setting is a predictor of both short and long-term mortality.


ACR 2019 Table 1 Short term mortality

Fig. 1: Long-term survival of patients with hyperuricemia and normo-uricemia following admission in an acute-care setting.


Disclosure: G. Breuer‬‏, None; M. Abu Sneineh‬‏, None; G. Nesher, None.

To cite this abstract in AMA style:

Breuer‬‏ G, Abu Sneineh‬‏ M, Nesher G. Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/uric-acid-level-as-a-predictor-of-long-term-mortality-in-advanced-age-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/uric-acid-level-as-a-predictor-of-long-term-mortality-in-advanced-age-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology